In vivo treatment of tumors using host-guest conjugated nanoparticles functionalized with doxorubicin and therapeutic gene pTRAIL

Biomaterials

Volumn 33, Issue 5, 2012, Pages 1428-1436

  Fan, Hui ^a,c   Hu, Qi Da ^b,d   Xu, Fu Jian ^e   Liang, Wen Quan ^c   Tang, Gu Ping ^b   Yang, Wan Tai ^e  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY   (China)

Author keywords

DNA; Doxorubicin; Gene therapy; PTRAIL; Vectors

Indexed keywords

ANTICANCER DRUG; CANCER THERAPY; CHEMOTHERAPEUTIC DRUGS; DELIVERY SYSTEMS; DOXORUBICIN; FUNCTIONALIZED; HOST-GUESTS; HUMAN TUMORS; IN-VIVO; INHIBITION OF TUMOR GROWTH; POTENTIAL APPLICATIONS; PTRAIL; SURVIVAL TIME; THERAPEUTIC EFFECTS; THERAPEUTIC EFFICACY; THERAPEUTIC GENES;

CELL DEATH; CHEMOTHERAPY; DISEASES; DNA; GENE ENCODING; PATIENT TREATMENT; TUMORS; VECTORS;

GENE THERAPY;

BETA CYCLODEXTRIN; DOXORUBICIN; NANOPARTICLE; POLYETHYLENEIMINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONFOCAL LASER MICROSCOPY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; GENE DELIVERY SYSTEM; HUMAN; HUMAN CELL; MOUSE; NICK END LABELING; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SURVIVAL TIME;

ADAMANTANE; ANIMALS; BETA-CYCLODEXTRINS; CELL DEATH; CELL LINE, TUMOR; DOXORUBICIN; FEMALE; FLOW CYTOMETRY; GREEN FLUORESCENT PROTEINS; HUMANS; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; NANOPARTICLES; NEOPLASMS; PLASMIDS; POLYETHYLENEIMINE; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

MUS;

EID: 83355163230     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.10.043     Document Type: Article

References (27)

1. Kentsis A., Gordon R.E.B., Borden K.L. Control of biochemical reactions through supramolecular RING domain self-assembly. Proc Natl Acad Sci USA 2002, 99:15404-15409.
2. Lehn J.M. Perspectives in supramolecular chemistry-from molecular recognition towards molecular information processing and self-organization. Angew Chem-Int Edit 1990, 29:1304-1319.
3. Zhang Z.X., Wang J.A., Wang X.L., Wang Y., Yang X.R. A sensitive choline biosensor with supramolecular architecture. Talanta 2010, 82:483-487.
4. Li J., Loh X.J. Cyclodextrin-based supramolecular architectures: syntheses, structures, and applications for drug and gene delivery. Adv Drug Deliv Rev 2008, 60:1000-1017.
5. Park I.K., Von Recum H.A., Jiang S.Y., Pun S.H. Supramolecular assembly of cyclodextrin-based nanoparticles on solid surfaces for gene delivery. Langmuir 2006, 22:8478-8484.
6. Zhang J.X., Ma P.X. Host-guest interactions mediated nano-assemblies using cyclodextrin-containing hydrophilic polymers and their biomedical applications. Nano Today 2010, 5:337-350.
7. Davis M.E., Zuckerman J.E., Choi C.H.J., Seligson D., Tolcher A., Alabi C.A., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1140.
8. Wang H., Wang S.T., Su H., Chen K.J., Armijo A.L., Lin W.Y., et al. A supramolecular approach for preparation of size-controlled nanoparticles. Angew Chem-Int Edit 2009, 48:4344-4348.
9. Villalonga R., Cao R., Fragoso A. Supramolecular chemistry of cyclodextrins in enzyme technology. Chem Rev 2007, 107:3088-3116.
10. Cal K., Centkowska K. Use of cyclodextrins in topical formulations: practical aspects. Eur J Pharm Biopharm 2008, 68:467-478.
11. Tang G.P., Guo H.Y., Alexis F., Wang X., Zeng S., Lim T.M., et al. Low molecular weight polyethylenimines linked by beta-cyclodextrin for gene transfer into the nervous system. J Gene Med 2006, 8:736-744.
12. Huang H.L., Yu H., Tang G.P., Wang Q.Q., Li J. Low molecular weight polyethylenimine cross-linked by 2-hydroxypropyl-gamma-cyclodextrin coupled to peptide targeting HER2 as a gene delivery vector. Biomaterials 2010, 31:1830-1838.
13. Díaz-Moscoso A., Vercauteren D., Rejman J., Benito J.M., Ortiz Mellet C., De Smedt S.C., et al. Insights in cellular uptake mechanisms of pDNA-polycationic amphiphilic cyclodextrin nanoparticles (CDplexes). J Control Release 2010, 143:318-325.
14. Janat-Amsbury M.M., Yockman J.W., Lee M., Kern S., Furgeson D.Y., Bikram M., et al. Combination of local, nonviral IL12 gene therapy and systemic paclitaxel treatment in a metastatic breast cancer model. Mol Ther 2004, 9:829-836.
15. Wang Y., Gao S.J., Ye W.H., Yoon H.S., Yang Y.Y. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater 2006, 5:791-796.
16. Chen A.M., Zhang M., Wei D., Stueber D., Taratula O., Minko T., et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 2009, 5:2673-2677.
17. Lee A.L., Wang Y., Cheng H.Y., Pervaiz S., Yang Y.Y. The co-delivery of paclitaxel and herceptin using cationic micellar nanoparticles. Biomaterials 2009, 30:919-927.
18. Lu X., Ping Y., Xu F.J., Li Z.H., Wang Q.Q., Chen J.H., et al. Bifunctional conjugates comprising beta-cyclodextrin, polyethylenimine, and 5-fluoro-2'- deoxyuridine for drug delivery and gene transfer. Bioconjug Chem 2010, 21:1855-1863.
19. Hu Q.D., Fan H., Ping Y., Liang W.Q., Tang G.P., Li J. Cationic supramolecular nanoparticles for co-delivery of gene and anticancer drug. Chem Commun 2011, 47:5572-5574.
20. Adler A.F., Leong K.W. Emerging links between surface nanotechnology and endocytosis: impact on nonviral gene delivery. Nano Today 2010, 5:553-569.
21. MacKay J.A., Chen M.N., McDaniel J.R., Liu W.G., Simnick A.J., Chilkoti A. Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection. Nat Mater 2009, 8:993-999.
22. Mintzer M.A., Simanek E.E. Nonviral vectors for gene delivery. Chem Rev 2009, 109:259-302.
23. Ashkenazi A., Holland P., Eckhardt S.G. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008, 26:3621-3630.
24. Cuello M., Ettenberg S.A., Nau M.M., Lipkowitz S. Synergistic induction of apoptosis by the combination of TRAIL and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol 2001, 81:380-390.
25. Cui D.D., Huang Y., Mao S.H. Synergistic antitumor effect of TRAIL and adriamycin on the human breast cancer cell line MCF-7. J Med Biol Res 2009, 2:854-862.
26. Lacour S., Hammann A., Wotawa A., Corcos L., Solary E. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res 2001, 61:1645-1651.
27. Song K.M., Chen Y.G., Goke R., Wilmen A., Seidel C., Goke A., et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med 2000, 191:1095-1103.